ICAD 2010: detection may hold the key to treatment

Abstract

The Alzheimer’s Association International Conference on Alzheimer’s Disease was held on July 10–15 in Honolulu (HI, USA). Over 3800 attendees participated, attending sessions that included more than 1700 posters and 200 oral presentations. The meeting, first organized in 1988 by Khalid Iqbal and Bengt Winblad, became an annual event in 2009, and under the current design includes not only well-established themes of interest, but investigator-initiated sessions also. The Alzheimer’s Association started managing the conference in 2000 in partnership with the founders, and abstracts for the meeting are published in the association’s journal, Alzheimer’s & Dementia. Key themes of this year’s conference included validation of biomarkers, drug development, the value of screening for cognitive loss and dementia and the proposal of a new criteria for Alzheimer’s disease.

Financial & competing interests disclosure

Mary Sano has been a consultant to the following companies: Medivation, Novartis, Pfizer, Bristol Myer Squbb. Esai Pharmaceitical, Elan, Genetech USA, UBC health care Analytics, INC, Takeda, Sanofi-Aventis, Bayer, and Medpace. No compensation was received from the above entities for attendance at the meeting. Mary Sano is a member of the program committee for the AAICAD meeting and received partial reimbursement for attendance at the meeting. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.